INTUITIVE SURGICAL INC (ISRG) Form 8-K — Oct 20, 2026
Intuitive Surgical reported Q3 2026 revenue of $3.05 billion, up 22% year over year, with procedure growth of approximately 15% across its da Vinci and Ion platforms. The company placed 546 da Vinci systems, including 315 da Vinci 5 units, and grew the da Vinci installed base 12% to 12,094 systems. Non-GAAP net income was $1.05 billion, or $3.00 per diluted share, up from $2.40 a year ago. GAAP net income fell to $523 million ($1.49 diluted EPS) because results included a $450 million pre-tax charge to settle the previously disclosed da Vinci antitrust class action, without admission of liability, pending court approval.
Key figures
- Eps
- 1.49
- Revenue
- 3048700000
- Guidance
- 2026 worldwide da Vinci procedure growth of approximately 14%-15% (closer to midpoint); non-GAAP gross margin 68.7%-69.3% including ~0.9% tariff impact; non-GAAP opex growth 11%-13%
- Net Income
- 522800000
- Revenue Yoy
- 22%
- Cash Position
- 6800400000
- Non gaap eps
- 3
- Procedure growth
- 15% (da Vinci 14%, Ion 31%)
- Share repurchases
- 7.8 million shares for $2.94 billion
- Ion installed base
- 1152
- Ion systems placed
- 56
- Non gaap net income
- 1054500000
- Da vinci installed base
- 12094
- Da vinci systems placed
- 546
- Non gaap eps prior year
- 2.4
- Da vinci 5 systems placed
- 315
- Gaap net income prior year
- 704400000
- Ieepa tariff refund benefit
- $22 million net of tax, or $0.06 per diluted share
- Litigation settlement charge
- 450000000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.